Anagenics Limited · ASX:AN1
Anagenics — Shareholder Meeting (November 2023)
10 slides from Anagenics's shareholder meeting presentation, Nov 1, 2023
Slide 1: Growing a portfolio of innovative health, beauty, and wellness brands
ASX: AN1 rsonal use only Growing a portfolio of innovative health, beauty, and wellness brands 2023 Annual General Meeting
Slide 2: Disclaimer
Disclaimer rsonal use only Forward Looking Statement and Disclosures. a recommendation by Anagenics or any other person in respect misrepresentation, no responsibility or liability or duty of care is, This presentation is not making any offer, inducement, of any matter whatsoever. While Anagenics be
Slide 3: Who is Anagenics?
WHO IS ANAGENICS? A premium beauty, health, and wellness company rsonal use only Our mission is to drive profitable growth through a portfolio of brands and commercialising everyday products. Product Brands B2B B2C IN-HOUSE Distribution and licensing E-commerce platforms We achieve this through crea
Slide 4: A desirable portfolio serving global markets
WHO IS ANAGENICS? A desirable portfolio serving global markets Underpinned by profitable, trusted, and validated leading brands rsonal use only 48% Gross margin PARTNERSHIPS 1,110 Accounts across ANZ $10m^ USA CHINA Total revenue & other income 22 employees ANZ 8 Brands exclusive distributor up 26%*
Slide 5: Anagenics has laid the foundations for sustainable profitability
FY23 RESULTS Anagenics has laid the foundations for sustainable profitability rsonal use only NOVEMBER 2021 APRIL 2023 JUNE 2023 JUNE 2023 AUGUST 2023 Underlying EBITDA1 improved +43% FY23 vs FY22 INORGANIC TALENT PROACTIVELY SOUGHT SOUGHT SYNERGIES ACQUISITION TO REDUCE LOSSES AND OPERATIONAL OF FA
Slide 6: Road to Profitability
FY23 RESULTS Road to Profitability rsonal use only ($’000) ($’000) ($’000) ($’000) ($’000) 20232 20223 2021 2020 2019 Revenue & Other Income 9,909 10,004 6,820 8,548 8,347 EBITDA – Underlying1 (1,661) (2,899) (2,715) (3,739) (3,590) Loss After Income Tax (2,667) (3,649) (3,387) (4,907) (5,910) Earni
Slide 7: Performance Highlights – FY23
FY23 RESULTS Key Up 26% $2.0M rsonal use only recruitments Revenue and other income from Total eComm sales $2.0M (2022: Appointment of CEO, Scott continuing operations (excluding $1.9M), in total up 5%. DTC Greasley, CFO Matthew Dudek Japan) was up 26% in FY23 to channel $0.9M (2022: $0.7M) – and no
Slide 8: FY24 initiatives
FY24 - THE PATH AHEAD FY24 initiatives rsonal use only Anagenics is working to accelerate: • Streamlining and simplifying platforms • Profiting from M&A • Growing Brands Integrate & onboard Proactively source Brand Development and Grow margins by Commitment to further Face MediGroup, M&A opportuniti
Slide 9: Earnings Accretive M&A Opportunities
FY24 - THE PATH AHEAD Earnings Accretive Accretive targets M&A Opportunities Profitable and values-based rsonal use only businesses at the right price AN1 is uniquely positioned to move quickly on opportunities that provide the ability to AN1 has clarity on Agility drive further operational efficien
Slide 10: Unlock growth opportunities with Anagenics
Unlock growth opportunities rsonal use only with Anagenics Authorised for release to the ASX by AN1 Board of Directors Anagenics Limited Suite 204, Level 2 55 Clarence Street Sydney, NSW, 2000 Sandy Beard Scott Greasley info@anagenics.com Chairman CEO & Managing Director anagenics.com p: +61 412 308